Forest Devices Announces Positive Study Results for Their Stroke Detection Technology
Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only available at highly specialized hospitals, and every minute of treatment delay increases the risk of death and permanent disability.
The study showed that, compared to the clinical exams currently used by medics in the field to make triage decisions, AlphaStroke was 28% - 40% superior at correctly identifying patients with LVO, and equally good as the clinical exams, at correctly ruling out patients with non-LVO diagnoses.
“The results from the EDGAR study are a high-water mark in the global effort to improve early identification of patients needing thrombectomy,” said Matt Kesinger, CEO of FDI. “As a former EMT on ambulances, I experienced the challenge of correctly identifying stroke patients with only a few clinical exam questions. The EDGAR study is the first study, in which a portable technology, designed specifically for LVO identification, has been shown to outperform clinical exams currently applied by EMT’s worldwide.”
“The EDGAR study shows AlphaStroke™ has the potential to dramatically improve the detection of large vessel occlusion stroke in the prehospital environment,” said Dr. Paulina Sergot, lead author of the study and Emergency Medicine physician at Memorial Hermann hospital in Houston, Texas, one of the hospitals participating in the EDGAR study.
“This technology will be a game-changer in the prehospital,” said senior study author Dr. Frank Peacock, Vice Chair for Research of Emergency Medicine, Baylor College of Medicine. “Easy, fast, and more accurate than clinical impression for the diagnosis of LVO, using AlphaStroke™ on ambulances will mean more stroke victims getting to the right hospital as soon as possible. Time is brain, and fast treatment is the only thing that can prevent death or permanent disability from stroke.”
FDI’s diagnostic platform, AlphaStroke™, is designed to support prehospital healthcare providers in identifying stroke.
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania and Calgary, Alberta that has developed AlphaStroke, the first prehospital stroke detection technology. The company strives to reduce functional disability from stroke by eliminating delays in stroke treatment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005078/en/
Contact information
Carmelo R. Montalvo
412.404.3769
pr@forestdevices.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 08:00:00 EET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
SymphonyAI and Matas Group are Redefining Health & Beauty in the Nordics With AI7.1.2026 07:07:00 EET | Press release
In the ever-evolving health and beauty landscape, Matas Group continues to set the standard for innovation and customer care. As the largest retailer in its sector across Denmark, Sweden, Finland, and Norway, Matas Group is committed to delivering unified, data-driven experiences to millions of customers — both online and in-store. That commitment now takes a leap forward as Matas selects SymphonyAI, a global leader in Vertical AI platforms, as its partner to modernize category management across the entire enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107270530/en/ Exterior of a Matas Group retail store in Scandinavia. The leading Nordic health and beauty retailer is expanding its category management capabilities through a new partnership with SymphonyAI. Following its acquisition of KICKS in 2023, Matas identified a need for technology that could simplify, scale, and unify processes across its diverse market
Lenovo Unveils Breakthrough Personal AI Super Agent, Novel Adaptive Concepts, and Next-Gen Device Innovations Spanning Mobile, Gaming, Consumer and Commercial Portfolios at CES 20267.1.2026 03:00:00 EET | Press release
At CES® 2026, Lenovo™ unveiled a sweeping lineup of innovations across its wide portfolio, introducing smarter new personal AI experiences, first-of-its-kind proofs-of-concept, and major updates across its gaming, mobile, consumer, and commercial devices. From ThinkPad™ to ThinkBook™, ThinkCentre™, Yoga™, IdeaPad™, Legion, and Motorola, Lenovo is showing how its Smarter AI for All vision is coming to life through more adaptive devices, bold new form factors, and AI software experiences designed to fit naturally into everyday life. The showcase is headlined by the debut of Lenovo and Motorola Qira, a new type of cross-device AI super agent that’s a Personal Ambient Intelligence System. “With Lenovo and Motorola Qira, we are entering a new era of personal AI: one designed around users, built on trust, and shaped by their control,” said Luca Rossi, President of Intelligent Devices Group, Lenovo. “At CES, personal AI comes to life across our portfolio, from breakthrough concepts and new sm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom